AR069417A1 - Piperidinas heteroaril - sustituidas - Google Patents
Piperidinas heteroaril - sustituidasInfo
- Publication number
- AR069417A1 AR069417A1 ARP080105089A ARP080105089A AR069417A1 AR 069417 A1 AR069417 A1 AR 069417A1 AR P080105089 A ARP080105089 A AR P080105089A AR P080105089 A ARP080105089 A AR P080105089A AR 069417 A1 AR069417 A1 AR 069417A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkoxy
- alkyl
- substituted
- cycloalkyl
- phenyl
- Prior art date
Links
- -1 monofluoromethyl Chemical group 0.000 abstract 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
- 125000001424 substituent group Chemical group 0.000 abstract 9
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000003545 alkoxy group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005368 heteroarylthio group Chemical group 0.000 abstract 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 150000003053 piperidines Chemical class 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se refiere a piperidinas heteroaril-sustituidas, a procedimientos para su preparacion, a su uso para el tratamiento y/o la profilaxis de enfermedades y a su uso para preparar medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular de enfermedades cardiovasculares y enfermedades tumorales. Reivindicacion 1: Compuestos de la formula (1) en la que: A representa un grupo de las formulas (2) donde es el punto de anclaje al anillo de piperidina, y * es el punto de anclaje a R2; R1representa fenilo, donde fenilo puede estar sustituido con 1 a 3 sustituyentes seleccionados independientemente unos de otros del grupo constituido por monofluorometilo, difluorometilo, trifluorometilo, monofluorometoxi, difluorometoxi, trifluorometoxi, monofluorometilsulfanilo, difluorometilsulfanilo, trifluorometilsulfanilo, metilsulfonilo, alquilo C1-4, alcoxi C1-4, alcoxi C1-4-carbonilo y cicloalquilo C3-6, donde alcoxi C2-4 puede estar sustituido con un sustituyente seleccionado a partir del grupo constituido por metoxi y etoxi, y donde cicloalquilo puede estar sustituido con 1 a 3 sustituyentes independientemente uno del otro seleccionados del grupo constituido por halogeno y alquilo C1-4, R2 representa hidrogeno, trifluorometilo, aminometilo, alquilo C1-6, alquenilo C2-6, alcoxicarbonilo C1-4, cicloalquilo C3-6, ciclopentenilo, heterociclilo de 4 a 6 miembros, fenilo, 1,3-benzodioxolilo, heteroarilo de 5 o 6 miembros o piridilaminocarbonilo, donde cicloalquilo, heterociclilo, fenilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes seleccionados independientemente uno del otro del grupo constituido por halogeno, ciano, amino, monofluorometilo, difluorometilo, trifluorometilo. monofluorometoxi, difluorometoxi, trifluorometoxi, monofluorometilsulfanilo, difluorometilsulfanilo, trifluorometilsulfanilo, alquilo C1-4, alcoxi C1-4, alquilamino C1-6, alcoxi C1-4-carbonilamino, cicloalquilo C3-6, heterociclilo de 4 a 6 miembros, fenilo y heteroarilo de 5 o 6 miembros, donde alquilamino puede estar sustituido con un sustituyente seleccionado del grupo constituido por alcoxi C1-4 y alquilamino C1-6, y donde alquilo C1-4 puede estar sustituido con un sustituyente seleccionado del grupo constituido por halogeno, hidroxilo, amino, aminocarbonilo, alcoxi C1-4, alquil C1-6-amino, alquiltio C1-4, alquil C1-4-carbonilo, alquil C1-4-carboniloxi, alquil C1-4-sulfonilo, alcoxi C1-4-carbonilo, alcoxi C1-4-carbonilamino, cicloalquilo C3-6, cicloalquil C3-6-amino, heterociclilo de 4 a 6 miembros, fenilo, fenoxi, heteroarilo de 5 o 6 miembros y heteroariltio de 5 o 6 miembros, donde cicloalquilo, heterociclilo, fenilo, fenoxi, heteroarilo y heteroariltio pueden estar sustituidos con 1 a 3 sustituyentes seleccionados independientemente uno del otro del grupo constituido por halogeno, ciano, hidroximetilo, monofluorometilo, difluorometilo, trifluorometilo, monofluorometoxi. difluorometoxi, trifluorometoxi, monofluorometilsulfanilo, difluorometilsulfanilo, trifluorometilsulfanilo alquilo C1-4 alcoxi C1-4, cicloalquilo C3-6, heterociclilo de 4 a 6 miembros, fenilo y heteroarilo de 5 o 6 miembros, R3 representa alquilo C1-6, alcoxi C1-6, alquil C1-6-amino, cicloalquilo C3-7, heterociclilo de 4 a 6 miembros, fenilo o heteroarilo de 5 o 6 miembros, donde alquilo, alcoxi C2-6 y alquilamino pueden estar sustituidos con un sustituyente seleccionado del grupo constituido por hidroxilo, amino, ciano y alcoxi C1-4, y donde cicloalquilo, heterociclilo, fenilo y heteroarilo pueden estar sustituidos con 1 a 3 sustituyentes seleccionados independientemente unos de otros del grupo constituido por halogeno, ciano, nitro, oxo, hidroxilo, amino, aminometilo, monofluorometilo, difluorometilo, trifluorometilo, monofluorometoxi, difluorometoxi, trifluorometoxi, monofluorometilsulfanilo, difluorometilsulfanilo, trifluorometilsulfanilo, hidroxicarbonilo, aminocarbonilo, alquilo C1-4, alcoxi C1-4, alquil C1-6-amino, alcoxi C1-4-carbonilo y alquil C1-4-aminocarbonilo, o una de sus sales, de sus solvatos o de los solvatos de sus sales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007057718A DE102007057718A1 (de) | 2007-11-30 | 2007-11-30 | Heteroaryl-substituierte Piperidine |
| DE102008010221A DE102008010221A1 (de) | 2008-02-20 | 2008-02-20 | Heteroaryl-substituierte Piperidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069417A1 true AR069417A1 (es) | 2010-01-20 |
Family
ID=40580130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105089A AR069417A1 (es) | 2007-11-30 | 2008-11-24 | Piperidinas heteroaril - sustituidas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US8119663B2 (es) |
| EP (1) | EP2227466B1 (es) |
| JP (1) | JP5450435B2 (es) |
| KR (1) | KR20100114018A (es) |
| CN (1) | CN101932577B (es) |
| AR (1) | AR069417A1 (es) |
| AT (1) | ATE506359T1 (es) |
| CA (1) | CA2706991A1 (es) |
| CL (1) | CL2008003473A1 (es) |
| DE (1) | DE502008003324D1 (es) |
| DK (1) | DK2227466T3 (es) |
| HR (1) | HRP20110510T1 (es) |
| PA (1) | PA8805201A1 (es) |
| PE (1) | PE20091026A1 (es) |
| PL (1) | PL2227466T3 (es) |
| PT (1) | PT2227466E (es) |
| TW (1) | TW200936135A (es) |
| UY (1) | UY31484A1 (es) |
| WO (1) | WO2009068214A2 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009014484A1 (de) | 2009-03-23 | 2010-09-30 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| DE102009022896A1 (de) * | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| DE102009022895A1 (de) * | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| DE102009022894A1 (de) * | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| DE102009022897A1 (de) * | 2009-05-27 | 2010-12-02 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Piperidine |
| EP2585441A4 (en) * | 2010-06-28 | 2013-10-09 | Hetero Research Foundation | PROCESS FOR OLMESARTAN MEDOXOMIL |
| KR20130043207A (ko) | 2010-07-22 | 2013-04-29 | 자프겐 인크. | 트리시클릭 화합물 및 이의 제조 및 사용 방법 |
| AU2011316550A1 (en) | 2010-10-12 | 2013-05-02 | Zafgen, Inc | Sulphonamide compounds and methods of making and using same |
| TW201300380A (zh) * | 2010-10-19 | 2013-01-01 | Comentis Inc | 抑制β－分泌酶活性之噁二唑化合物及其使用方法 |
| WO2012103333A1 (en) | 2011-01-26 | 2012-08-02 | Zafgen Corporation | Tetrazole compounds and methods of making and using same |
| KR20140053013A (ko) | 2011-05-06 | 2014-05-07 | 자프겐 인크. | 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법 |
| PH12013502261A1 (en) | 2011-05-06 | 2022-10-26 | Zafgen Inc | Partially saturated tricyclic compounds and methods of making and using same |
| AU2012253760B2 (en) | 2011-05-06 | 2016-02-04 | Zafgen, Inc. | Tricyclic pyrazole sulfonamide compounds and methods of making and using same |
| BR112014017780A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos |
| WO2013109739A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| US9868717B2 (en) | 2012-11-05 | 2018-01-16 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
| CN104870433A (zh) | 2012-11-05 | 2015-08-26 | 扎夫根股份有限公司 | 三环化合物及其制备方法和用途 |
| JP6169716B2 (ja) | 2012-11-05 | 2017-07-26 | ザフゲン，インコーポレイテッド | 肝疾患を治療する方法 |
| CN103965095A (zh) * | 2013-02-04 | 2014-08-06 | 艾琪康医药科技（上海）有限公司 | 1-r1-3-r2-4-氟哌啶及其衍生物的制备方法 |
| CN104341590A (zh) * | 2013-08-01 | 2015-02-11 | 韩冰 | 一种树枝状高分子化合物及其制备和用途 |
| TW202100526A (zh) | 2019-03-06 | 2021-01-01 | 日商第一三共股份有限公司 | 吡咯并吡唑衍生物 |
| WO2022232093A1 (en) | 2021-04-30 | 2022-11-03 | Mind Medicine, Inc. | Lsd salt crystal forms |
| AU2022331317B2 (en) | 2021-08-19 | 2025-09-11 | Definium Therapeutics US, Inc. | IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA951618B (en) * | 1994-03-04 | 1996-08-27 | Lilly Co Eli | Antithrombotic agents |
| US5767144A (en) * | 1994-08-19 | 1998-06-16 | Abbott Laboratories | Endothelin antagonists |
| KR100508200B1 (ko) * | 1996-02-13 | 2005-12-16 | 아보트 러보러터리즈 | 엔도텔린길항제로서의벤조-1,3-디옥솔릴-및벤조푸라닐치환된피롤리딘유도체및이를함유하는약제 |
| WO1997036873A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone |
| US6403612B2 (en) * | 2000-01-31 | 2002-06-11 | Merck & Co., Inc. | Thrombin receptor antagonists |
| WO2002085855A1 (fr) * | 2001-04-19 | 2002-10-31 | Eisai Co., Ltd. | Derives de 2-iminopyrrolidine |
| NZ531733A (en) * | 2001-10-15 | 2006-04-28 | Janssen Pharmaceutica Nv | Substituted 4-phenyl-4-[1H-imidazol-2-YL]- piperidine derivatives for reducing ischaemic damage |
| US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
| WO2006002350A1 (en) | 2004-06-24 | 2006-01-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| WO2006012226A2 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | N-substituted piperidines and their use as pharmaceuticals |
| US20060009471A1 (en) | 2004-06-24 | 2006-01-12 | Wenqing Yao | Amido compounds and their use as pharmaceuticals |
| CN101080226A (zh) | 2004-08-10 | 2007-11-28 | 因塞特公司 | 酰氨基化合物及它们作为药物的用途 |
| DE102004045796A1 (de) * | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
| WO2006051623A1 (ja) * | 2004-11-09 | 2006-05-18 | Eisai Co., Ltd. | トロンビン受容体アンタゴニストを有効成分とするくも膜下出血に伴う血管攣縮の治療剤 |
| WO2007038138A2 (en) | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| KR20080091503A (ko) | 2006-01-31 | 2008-10-13 | 인사이트 코포레이션 | 아미도 화합물 및 약제로서의 이의 용도 |
| TW200808807A (en) | 2006-03-02 | 2008-02-16 | Incyte Corp | Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same |
| WO2007130898A1 (en) * | 2006-05-01 | 2007-11-15 | Incyte Corporation | TETRASUBSTITUTED UREAS AS MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 |
-
2008
- 2008-11-20 HR HR20110510T patent/HRP20110510T1/hr unknown
- 2008-11-20 DE DE502008003324T patent/DE502008003324D1/de active Active
- 2008-11-20 KR KR1020107014447A patent/KR20100114018A/ko not_active Withdrawn
- 2008-11-20 WO PCT/EP2008/009792 patent/WO2009068214A2/de not_active Ceased
- 2008-11-20 CA CA2706991A patent/CA2706991A1/en not_active Abandoned
- 2008-11-20 PT PT08854224T patent/PT2227466E/pt unknown
- 2008-11-20 EP EP08854224A patent/EP2227466B1/de not_active Not-in-force
- 2008-11-20 DK DK08854224.6T patent/DK2227466T3/da active
- 2008-11-20 PL PL08854224T patent/PL2227466T3/pl unknown
- 2008-11-20 JP JP2010535272A patent/JP5450435B2/ja not_active Expired - Fee Related
- 2008-11-20 CN CN2008801260263A patent/CN101932577B/zh not_active Expired - Fee Related
- 2008-11-20 AT AT08854224T patent/ATE506359T1/de active
- 2008-11-21 CL CL2008003473A patent/CL2008003473A1/es unknown
- 2008-11-24 AR ARP080105089A patent/AR069417A1/es unknown
- 2008-11-24 UY UY31484A patent/UY31484A1/es not_active Application Discontinuation
- 2008-11-24 PE PE2008001960A patent/PE20091026A1/es not_active Application Discontinuation
- 2008-11-25 PA PA20088805201A patent/PA8805201A1/es unknown
- 2008-11-25 US US12/323,454 patent/US8119663B2/en not_active Expired - Fee Related
- 2008-11-28 TW TW097146090A patent/TW200936135A/zh unknown
-
2012
- 2012-02-20 US US13/400,491 patent/US20120214788A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL2227466T3 (pl) | 2011-09-30 |
| PE20091026A1 (es) | 2009-07-26 |
| EP2227466B1 (de) | 2011-04-20 |
| CN101932577A (zh) | 2010-12-29 |
| EP2227466A2 (de) | 2010-09-15 |
| CA2706991A1 (en) | 2009-06-04 |
| WO2009068214A2 (de) | 2009-06-04 |
| JP5450435B2 (ja) | 2014-03-26 |
| CN101932577B (zh) | 2013-07-17 |
| WO2009068214A3 (de) | 2009-08-20 |
| PA8805201A1 (es) | 2010-02-12 |
| US20120214788A1 (en) | 2012-08-23 |
| KR20100114018A (ko) | 2010-10-22 |
| ATE506359T1 (de) | 2011-05-15 |
| DK2227466T3 (da) | 2011-08-08 |
| JP2011504889A (ja) | 2011-02-17 |
| CL2008003473A1 (es) | 2009-08-14 |
| HRP20110510T1 (hr) | 2011-08-31 |
| US8119663B2 (en) | 2012-02-21 |
| US20090306139A1 (en) | 2009-12-10 |
| PT2227466E (pt) | 2011-07-01 |
| DE502008003324D1 (de) | 2011-06-01 |
| HK1152311A1 (en) | 2012-02-24 |
| UY31484A1 (es) | 2009-07-17 |
| TW200936135A (en) | 2009-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069417A1 (es) | Piperidinas heteroaril - sustituidas | |
| AR058703A1 (es) | Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer | |
| AR067327A1 (es) | Derivados de piperidina / piperazina | |
| AR082799A1 (es) | Derivados de quinolina y quinoxalina como inhibidores de quinasa | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| ECSP10010473A (es) | Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización | |
| AR067646A1 (es) | Ariloxazoles sustituidos y su uso | |
| AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
| AR076547A1 (es) | Compuestos bis-amida como insecticidas | |
| AR064454A1 (es) | Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer. | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| AR078163A1 (es) | Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes | |
| AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. | |
| AR072184A1 (es) | Derivados de oxadiazol como agonistas del receptor s1p1 | |
| AR069512A1 (es) | Pirazolopirimidinas sustituidas para el tratamiento de trastornos del snc. composiciones farmaceuticas | |
| AR082826A2 (es) | Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos | |
| AR055606A1 (es) | Derivados de benzoquinazolina | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| AR066153A1 (es) | Derivados de piperidina / piperazina | |
| AR078947A1 (es) | Compuestos de diazinil-pirazolilo y procesos de preparacion de los mismos | |
| AR076692A1 (es) | Piperidinas sustituidas | |
| AR080596A1 (es) | Compuestos alquilamido y composiciones farmaceuticas | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| AR077486A2 (es) | Compuesto derivado de isotiazol sustituido composicion fungicida insecticida acaricida molusquicida o nematicida quelo comprende y metodo para combatir y controlar hongos insectos acaros nematodos o moluscos usando dicho compuesto o dicha composicion | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |